Witney Gazette | European Approval for Gilead Drug - Analyst Blog NASDAQ The EC cleared the drug as an all-oral therapy for treating patients affected with genotypes 1, 2, 3, 4, 5 or 6 of the virus. Sovaldi in combination with ribavirin can also be used to treat chronic HCV patients awaiting liver transplantation to prevent ... EU clears Gilead's hepatitis C therapy Sovaldi European Commission grants marketing authorization for Gilead's Sovaldi Gilead Sciences Inc receives marketing authorisation for Sovaldi for treating ... |
